Brief: GenSight Biologics Announces Publication of Results from LUMEVOQ REVERSE Pivotal Phase III Trial

Gensight Biologics SA

10/12/2020 06:38

Dec 10 (Reuters) - GENSIGHT BIOLOGICS SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS ANNOUNCES PUBLICATION OF RESULTS FROM
LUMEVOQ® REVERSE PIVOTAL PHASE III TRIAL AND NON-HUMAN PRIMATE
STUDY IN SCIENCE TRANSLATIONAL MEDICINE
    * NON-HUMAN PRIMATE STUDY CLARIFIES MECHANISM BEHIND
CONTRALATERAL
EFFECT
    * FIRST PUBLICATION BASED ON PHASE III DATA TO DOCUMENT
SUSTAINED
AND CLINICALLY MEANINGFUL BILATERAL IMPROVEMENT IN VISUAL ACUITY
FROM UNILATERAL INJECTION OF A GENE THERAPY
    * AGENCY'S DECISION IS EXPECTED IN Q4 2021
    * FINDINGS FROM REVERSE TRIAL AND NON-HUMAN PRIMATE STUDY
WERE KEY
COMPONENTS OF DATA PACKAGE SUBMITTED IN SEPT 2020 TO EUROPEAN
MEDICINES AGENCY

Source text for Eikon:  ID:nBw7mk99Da 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))